An anonymous director reports

MINDMED TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS DATA UPDATE FOR MM120

Mind Medicine (MindMed) Inc. will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in generalized anxiety disorder (GAD), including 12-week topline safety, efficacy and durability results from the company's phase 2b trial and results from the company's phase 1 pharmacokinetics bridging trial to support the advancement of the MM120 oral dissolving tablet (ODT) formulation into pivotal clinical trials.

A live question and answer session will follow the program.

The event will begin at 8 a.m. ET on Thursday, March 7, 2024. The webcast and slides will be accessible live under news and events on the investors page of the company's website. A replay of the event will be available on MindMed's website.

About Mind Medicine (MindMed) Inc.

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Its mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. It is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.